Hikal’s Bengaluru API Facility Receives Swissmedic GMP Certification, Strengthening Global Market Reach

Hikal Limited’s Bengaluru API facility receives Swissmedic GMP certification, strengthening its regulatory standing and expanding opportunities in European pharmaceutical markets.

Pune, October 30, 2026: Hikal Limited has announced that its Active Pharmaceutical Ingredient (API) manufacturing facility in Bengaluru has received a Certificate of Good Manufacturing Practice (GMP) Compliance from Swissmedic, the Swiss Agency for Therapeutic Products. The certification marks an important development in the company’s efforts to strengthen its global pharmaceutical business and expand its presence in regulated international markets.

Announced on October 30, 2026, the certification confirms that Hikal’s Bengaluru facility meets the Good Manufacturing Practice requirements under the Mutual Recognition Agreement between the European Union and Switzerland.

The latest recognition adds to the facility’s existing regulatory credentials following successful inspections by Brazil’s ANVISA and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). These recognitions further strengthen the facility’s regulatory standing and support the company’s ability to serve a broader customer base across international markets.

According to Hikal, the Swissmedic certification is expected to create additional opportunities with pharmaceutical customers in Europe and other regulated markets. It also supports the company’s strategy of diversifying the geographical footprint of its pharmaceutical business while building resilience against geopolitical and international trade uncertainties.

Commenting on the development, Sameer Hiremath, Chairman and Managing Director of Hikal Limited, said that the certification reflects the quality systems established at the Bengaluru facility. He highlighted that the recognition represents an important step towards expanding the company’s global pharmaceutical business and developing new customer opportunities.

Hiremath also reiterated that quality, regulatory compliance and manufacturing excellence remain central to Hikal’s long-term customer partnerships.

Established in 1988, Hikal Limited operates across the pharmaceutical, animal health, biotechnology, personal care and specialty chemical industries. The company manufactures and supplies active ingredients, intermediates and biocides to the global life sciences industry.

Hikal operates five manufacturing facilities in India, located at Taloja and Mahad in Maharashtra, Panoli in Gujarat, and Jigani in Bengaluru. The company also has a Research and Technology Centre in Pune.

The company stated that its manufacturing facilities have undergone inspections and certifications by global regulatory authorities. Hikal has also received Responsible Care certification and an EcoVadis Gold Medal rating, placing it among the top five per cent of companies assessed globally for sustainability performance.

With the latest Swissmedic recognition, Hikal aims to further strengthen its international regulatory presence and expand business opportunities across global pharmaceutical markets.

Social media Handles :
Instagram
Youtube
Facebook
Twitter

Also Read- Pune